SCHEMBL4302243

SCHEMBL4302243

O=c1cnc2cc(F)cnc2[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 3/20 0.40
MAPKAPK2 P49137 1/20 0.40
CSNK2A1 P68400 1/20 0.40
PLK3 Q9H4B4 1/20 0.40
POLB P06746 2/20 0.38
ALDH1A1 P00352 3/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36
GLA P06280 1/20 0.36
PMP22 Q01453 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GSK3A P49840 3/20 0.35
GSK3B P49841 3/20 0.35
CDK5 Q00535 3/20 0.35
CDK1 P06493 2/20 0.35
CCNB2 O95067 1/20 0.35
CCNB1 P14635 1/20 0.35
CDK5R1 Q15078 1/20 0.35
CCNB3 Q8WWL7 1/20 0.35
PRKD3 O94806 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL932780 0.77 DYRK1A (0.55) RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1
SCHEMBL707948 0.72 DAO (0.39) RPS6KA3MAPKAPK2CSNK2A1PLK3POLB
SCHEMBL5659171 0.72 SNCA (0.40) POLBABL1PDE3BPDE3ADAO
SCHEMBL13290171 0.71 PRKD3 (0.61) RPS6KA3GSK3AGSK3BCDK5CDK1
SCHEMBL31425375 0.71 PRKD3 (0.61) RPS6KA3GSK3AGSK3BCDK5CDK1
SCHEMBL21597045 0.69 CDK5 (0.37) RPS6KA3POLBALDH1A1KDM4EGLA
SCHEMBL12777923 0.69 SNCA (0.33) RPS6KA3GSK3AGSK3BCDK5CDK1
SCHEMBL29433980 0.68 ALDH1A1 (0.42) RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1
SCHEMBL706055 0.68 MAPKAPK2 (0.50) RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1
SCHEMBL1378724 0.68 MAPKAPK2 (0.42) RPS6KA3MAPKAPK2CSNK2A1PLK3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071592-B2 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2011-12-06 US disclosed
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-1992628-A1 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2008-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES ETFA, NQO2, GNAQ RPS6KA3 1519/4885MAPKAPK2 3756/4885CSNK2A1 4457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.